Zealand Pharma A/S ADR (ZEAL)

Currency in USD
17.59
0.00(0.00%)
Closed·
Showing Zealand Pharma ADR historical data. For real-time data please try another search
Day's Range
17.4718.07
52 wk Range
17.4718.07
Key Statistics
Prev. Close
17.59
Open
18.03
Day's Range
17.47-18.07
52 wk Range
17.47-18.07
Volume
-
Average Volume (3m)
3.08K
1-Year Change
0%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock

Zealand Pharma A/S ADR News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Zealand Pharma A/S ADR Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.

Industry
-
Sector
-
Employees
424

Zealand Pharma A/S ADR Earnings Call Summary for Q2/2025

  • Revenue reached 9.1B DKK, driven by Roche collaboration; cash position increased to 16.6B DKK, bolstering R&D capabilities
  • Obesity pipeline progress: phase 2 data for patreotide expected by end of 2025, phase 3 trials planned for 2026
  • Financial guidance: 2-2.5B DKK in net operating expenses; revenue forecast to grow 148% in FY 2025
  • New leadership appointments to strengthen scientific and development capabilities; CEO emphasizes 'pivotal new chapter'
  • Analysts maintain strong buy consensus; price targets range from $62.69 to $175.52, suggesting significant upside potential
Last Updated: 14/08/2025, 14:26
Read Full Transcript

Earnings

Latest Release
Aug 14, 2025
EPS / Forecast
105.61 / --
Revenue / Forecast
9.09B / --
EPS Revisions
Last 90 days

ZEAL Income Statement

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.